Bladder cancer ranks among the most common cancers globally. At diagnosis, 75% of
patients have non-muscle-invasive bladder cancer (NMIBC). Patients with low-risk NMIBC …

Bladder cancer is the tenth most prevalent malignancy worldwide, with a significant mortality
burden. Urothelial carcinoma (UC) is the most common histological subtype, and treatment …

Abstract Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment
failure, suggesting that patients could benefit from a more personalized treatment approach …

Purpose Cytology and cystoscopy, the current gold standard for diagnosing urothelial
carcinomas, have limits: cytology has high interobserver variability with moderate or not …

Bladder cancer, a prevalent malignancy affecting the urinary system, arises from the tissues
of the bladder, a hollow organ responsible for storing urine (see Image. Bladder Cancer …

To reduce recurrence rate after transurethral resection of bladder tumor, long-term
intravesical instillations of Bacillus Calmette-Guérin (BCG) and/or chemotherapeutic drugs is …

Urologic cancers, particularly kidney, bladder, and prostate cancer, have a growing
incidence and account for about a million annual deaths worldwide. Treatments, including …

Aberrant expression of glycans, ie, oligosaccharide moiety covalently attached to proteins or
lipids, is characteristic of various cancers, including urothelial ones. The binding of lectins to …

In the management of non‐muscle invasive bladder cancer (NMIBC), disease progression
and long‐term control are determined by the intensity of delivered treatment and …

Generation of organoids from urinary tract tumor samples was pioneered a few years ago.
We generated organoids from two upper tract urothelial carcinomas and from one bladder …